3/29
09:13 am
adag
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/29
09:00 am
adag
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
High
Report
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
3/15
09:45 pm
adag
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Low
Report
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
3/7
04:09 pm
adag
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board [Yahoo! Finance]
Low
Report
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board [Yahoo! Finance]
3/7
04:01 pm
adag
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Low
Report
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
2/27
08:08 am
adag
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 [Financial Post (Toronto, Ontario, Canada)]
2/27
08:04 am
adag
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 [Yahoo! Finance]
Low
Report
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 [Yahoo! Finance]
2/27
08:00 am
adag
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Low
Report
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
2/9
06:17 am
adag
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl
Low
Report
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl
2/9
06:00 am
adag
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl
Low
Report
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl